TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 331868
Drug: Nitrazepam 5
Normalized name: nitrazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrazepam 5 mg and 10 mg
Study: 26094394
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement rekicen‐RD® in combination with antibacterial therapy
Study: 15035551
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of terbutaline daily for 15 days starting on the day of oocyte retrieval (Group I)
Study: 15035551
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of ritodrine daily for 15 days (Group II)
Study: 7092752
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Group III)
Study: 7697065
Drug: Tricyclic antidepressants
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic antidepressants or cognitive-behavioral psychotherapy
Study: 30482676
Drug: Herbal tea
Normalized name: Senna Oral Powder for Suspension [CORRECTOL HERBAL TEA LAXATIVE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal tea (Astragali Radix, Angelicae gigantis Radix, Zizyphi Fructus) consumed twice daily for 4 weeks
Study: 6118171
Drug: Atenolol 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 0.2 mg/kg
Study: 6118171
Drug: Betaxolol 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.15 mg/kg
Study: 6118171
Drug: Betaxolol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 0.6 mg/kg
Study: 436923
Drug: Practolol 1
Normalized name: (±)-practolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practolol 1 mg/kg
Study: 26710009
Drug: Silicone implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone implants
Study: 26710009
Drug: Saline implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline implants
Study: 11869201
Drug: Long pulse
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long pulse 532 nm potassium tritanyl phosphate (KTP) laser treatment for perialar vessels
Study: 11869201
Drug: Long pulse
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long pulse 532 nm potassium tritanyl phosphate (KTP) laser treatment for spider naevi
Study: 9022602
Drug: Oral estrone
Normalized name: Estrone
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral estrone sulfate
Study: 8566257
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2
Study: 23367230
Drug: NMES therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NMES therapy of quadriceps femoris and tibialis anterior muscles
Study: 18497346
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral mifepristone
Study: 15587176
Drug: Ropivacaine 0.9375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.9375 mg x kg(‐1)
Study: 15587176
Drug: Ropivacaine 0.5625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5625 mg x kg(‐1)
Study: 10689949
Drug: Prednisolone (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (maximum of 15 mg daily)
Study: 3276591
Drug: Nadolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (40 to 120 mg per day)
Study: 21707560
Drug: Clonidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (150 μg) added to epidural solution
Study: 14980556
Drug: Sulpiride (dopaminergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (dopaminergic drug treatment)
Study: 9273190
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy with daily doses of carboplatin (20 to 25 mg/m2/d over 45 or 10 min) and accelerated chest irradiation (60 to 64 Gy over 4 weeks, 2 Gy per fraction)
Study: 9273190
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy with daily doses of carboplatin and accelerated chest irradiation
Study: 3306068
Drug: Danazol 200
Normalized name: danazol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danazol 200 mg per day
Study: 27038608
Drug: CT-P13 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT-P13 (3 mg/kg)
Study: 27038608
Drug: RP (3
Normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RP (3 mg/kg)
Study: 19947898
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg quercetin/day with 125 mg vitamin C/day
Study: 19947898
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg quercetin/day with 250 mg vitamin C/day
Study: 20428412
Drug: Duloxetine 60/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60/120 mg once daily
Study: 10397378
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 600 mg clomethiazole edisylate (390 mg clomethiazole base)
Study: 10397378
Drug: Both oral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both oral and rectal administration of 600 mg clomethiazole edisylate
Study: 31869656
Drug: Primary care-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care-based treatment
Study: 18579924
Drug: Both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both active and sham treatments
Study: 18579924
Drug: Monochromatic infrared
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monochromatic infrared energy treatment
Study: 16007595
Drug: Chemotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specific dosage and duration not provided)
Study: 12401632
Drug: Clonidine 15-45
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 15-45 micro g
Study: 10667283
Drug: Amitriptyline (AMI)
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amitriptyline (AMI) at 1.6 mg/kg/day
Study: 2082953
Drug: Hydergine‐LC (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydergine‐LC (1 mg orally three times daily for 24 weeks)
Study: 30654808
Drug: Chloroquine (CQ)
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine (CQ) total 25 mg/kg over 3 days
Study: 27605986
Drug: Buccal corticotomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal corticotomy
Study: 27605986
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no buccal corticotomy)
Study: 22623468
Drug: No intracanal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intracanal medication (Group B)
Study: 16006029
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) 10-80 mg/day
Study: 29426035
Drug: Cognitive Anxiety
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Anxiety Sensitivity Treatment (CAST + cognitive bias modification)
Study: 20811917
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg fentanyl
Study: 20811917
Drug: 50 μg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 μg fentanyl
Study: 15780701
Drug: Sertraline, 50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline, 50-150 mg/day, continuous dosing throughout the menstrual cycle
Study: 7223659
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg slow release oxprenolol, once daily for 1 month
Study: 7223659
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg propranolol, four times daily for 1 month
Study: 7223659
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg propranolol, four times daily
Study: 22094298
Drug: Primary surgical
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary surgical treatment for advanced glaucoma
Study: 19761838
Drug: Reformulated killed
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated killed oral cholera vaccine (1 dose)
Study: 19761838
Drug: Reformulated killed
Normalized name: Tarsum Reformulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reformulated killed oral cholera vaccine (2 doses)
Study: 15339752
Drug: Unopposed transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed transdermal estradiol at 0.014 mg/d (n = 208)
Study: 328033
Drug: Diflunisal 375
Normalized name: diflunisal 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 375 mg twice daily
Study: 29343131
Drug: Plecanatide 6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plecanatide 6 mg
Study: 19887582
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum cholesterol (<200 mg/dL)
Study: 9926771
Drug: HA-coated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated implants that were mobile at placement
Study: 9926771
Drug: Non-HA-coated implants
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-HA-coated implants that were mobile at placement
Study: 9926771
Drug: All implants
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All implants (mobile or immobile) that integrated
Study: 9926771
Drug: HA-coated implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-coated implants (mobile)
Study: 791038
Drug: ethyl linoleate
Normalized name: Ethyl linoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ethyl linoleate agent (hELate) applied at a dose of 25 mg/kg only once after burn
Study: 28478975
Drug: Adalimumab 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 0.8 mg/kg
Study: 22573729
Drug: Daily cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cigarette smokers
Study: 30973790
Drug: Tamoxifen 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 5 mg/d
Study: 16382122
Drug: Fenretinide 200
Normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenretinide 200 mg/d
Study: 8265321
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccines (AC)
Study: 8265321
Drug: Monocomponent PT
Normalized name: PT-2385
DrugBank: PT-2385 (DB16055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monocomponent PT vaccine
Study: 3103662
Drug: Fresh gas
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh gas flow (FGF) of 70 ml kg‐1 min‐1
Study: 28883225
Drug: Carvedilol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (2.5 mg/5 mg/20 mg)
Study: 23363386
Drug: Levothyroxine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine administration with breakfast
Study: 25179689
Drug: palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: palonosetron 0.25 mg
Study: 14504060
Drug: ondansetron 32
Normalized name: ondansetron 32 MG in 50 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 32 mg
Study: 10893654
Drug: Cizolirtine citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cizolirtine citrate (E-4018) 50 mg
Study: 10893654
Drug: Cizolirtine citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cizolirtine citrate (E-4018) 100 mg
Study: 10893654
Drug: Cizolirtine citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cizolirtine citrate (E-4018) 150 mg
Study: 4022214
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (600 mg daily for 30 days)
Study: 25247929
Drug: Intravenous ferric‐carboxymaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ferric‐carboxymaltose (2 ml, 100 mg)
Study: 20007337
Drug: Flaxseed bread
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed bread (25 g of flaxseed, 46 mg lignans)
Study: 12792350
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of tenofovir DF once daily
Study: 1847127
Drug: External beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiotherapy as hyperfractionated treatment (1.2 Gy twice daily, 4 hours separation, 5 days per week, 24.0 Gy total) with similar chemotherapy.
Study: 1847127
Drug: Induction regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction regimen with cycles of radiolabeled antibody therapy (30 mCi I-131 antiferritin, Day 0, and 20 mCi, Day 5).
Study: 11732382
Drug: tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: tenoxicam 40 mg intravenously (i.v.)
Study: 11732382
Drug: tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: tenoxicam 40 mg intramuscularly (i.m.)
Study: 11732382
Drug: piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: piroxicam 40 mg intramuscularly (i.m.)
Study: 9218667
Drug: Stepped‐care antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped‐care antihypertensive drug therapy (chlorthalidone 12.5-25 mg or matching placebo, atenolol 25-50 mg or matching placebo)
Study: 9218667
Drug: Stepped‐care antihypertensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped‐care antihypertensive drug therapy (for patients with prior MI)
Study: 7970063
Drug: Thymopentin-TP5 in
Normalized name: Thymopentine
DrugBank: Thymopentin (DB11996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymopentin-TP5 in addition to antibiotic prophylaxis
Study: 2885462
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy alone
Study: 3121487
Drug: DOM (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOM (5 mg/h infusion)
Study: 3121487
Drug: GHRH (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (50 micrograms i.v.) plus DOM (5 mg/h i.v.)
Study: 29974278
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (OK + atropine 0.01% ophthalmic solution)
Study: 27001471
Drug: Test group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test group (tablet containing 20 mg of lactoferrin, 2.6 mg of lactoperoxidase, and 2.6 mg of glucose oxidase)
Study: 24793963
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo tablet)
Study: 23876539
Drug: Rectal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal misoprostol plus perivascular vasopressin
Study: 18851773
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT)
Study: 16556541
Drug: Three near
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three near zero-order controlled-release pseudoephedrine hydrochloride formulations
Study: 16556541
Drug: Three formulations
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three formulations
Study: 1976875
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin
Study: 25583364
Drug: Sertindole (12-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertindole (12-20 mg)
Study: 14503664
Drug: Intranasal doses
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal doses of IS-159 (1, 2, 4, and 6 mg) administered twice at an interval of 4 hours
Study: 6418181
Drug: Slow-release capsule
Normalized name: Bontril 105mg Slow-Release Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release capsule of ketoprofen lysine (160 mg)
Study: 6418181
Drug: Conventional capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional capsules of ketoprofen lysine (Artrosilene®) (160 mg)
Study: 31081485
Drug: ParkinSong intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ParkinSong intervention (weekly dosage)
Study: 31081485
Drug: ParkinSong intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ParkinSong intervention (monthly dosage)
Study: 30139035
Drug: Hydromorphone supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone supplement with dexmedetomidine 1 μg/kg group (D1 group)
Study: 25954844
Drug: Oral A.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral A. montana (Alpine Pharmaceuticals)
Study: 21808284
Drug: Nasal spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray nicotine replacement therapy
Study: 20949341
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules taken intact with water under fasting conditions
Study: 20949341
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules sprinkled on apple sauce
Study: 20949341
Drug: Morphine sulfate
Normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulfate and naltrexone hydrochloride extended release capsules under all treatment conditions
Study: 17619791
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS), beclomethasone dipropionate 250 microg/day
Study: 15895834
Drug: Experimental injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental injection of 0.5 mL of hypertonic (6%) saline
Study: 15895834
Drug: Control injection
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injection of 0.5 mL isotonic (0.9%) saline
Study: 17678570
Drug: Soya-based capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya-based capsules (35 mg isoflavones equivalent aglycone)
Study: 17678570
Drug: Soya-based cheese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soya-based cheese (35 mg isoflavones equivalent aglycone)
Study: 10553821
Drug: Nicardipine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 0.25 mg IV bolus
Study: 10553821
Drug: Nicardipine 2.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 2.00 mg IV bolus
Study: 6182412
Drug: Nicardipine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine (all doses)
Study: 29855695
Drug: Chemoimmunotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoimmunotherapy (group A, immunotherapy arm)
Study: 29855695
Drug: Chemotherapy (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (group B, control arm)
Study: 20860888
Drug: Antidepressants (SSRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (SSRIs prescribed by GP)
Study: 17473917
Drug: Atacicept (2.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (2.1, 70, 210 or 630 mg)
Study: 17473917
Drug: Atacicept (70,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atacicept (70, 210, 630 mg)
Study: 350346
Drug: Bromhexine 24
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine 24 mg/day
Study: 350346
Drug: Bromhexine 48
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine 48 mg/day
Study: 25854012
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) applied to Sanyinjiao (SP 6), Zigong (EX CA 1), Zhongji (CV 3), and Guanyuan (CV 4), treatment given once every two days until egg collection, needles retained for 30 min each time
Study: 28161352
Drug: Solifenacin 5
Normalized name: solifenacin 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solifenacin 5 mg (escalated to 10 mg at week 6)
Study: 16698413
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment every 2 months for 12 months (total of 7 treatments)
Study: 3398127
Drug: Postoperative course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative course of oral antibiotics (group 2)
Study: 3398127
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (controls, group 1)
Study: 20529983
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg hyperbaric 2% prilocaine
Study: 20529983
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg hyperbaric 2% prilocaine
Study: 16603098
Drug: Clotrimazole (antimycotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clotrimazole (antimycotic agent)
Study: 9520227
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg q.i.d.) plus Codeine (40 mg q.i.d.)
Study: 9520227
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg q.i.d.) plus Imipramine (10 or 25 mg t.i.d.)
Study: 2622580
Drug: Ofloxacin 600
Normalized name: ofloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 600 mg/day for 3 days
Study: 2622580
Drug: Ofloxacin 300
Normalized name: ofloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 300 mg/day for 3 days
Study: 2622580
Drug: Ofloxacin 600
Normalized name: ofloxacin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 600 mg/day for 5 days
Study: 1091029
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of adenine infused intravenously over one hour
Study: 1091029
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg of adenine infused intravenously over one hour
Study: 28606267
Drug: Lipid‐containing carbomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid‐containing carbomer gel (Group C)
Study: 28606267
Drug: Conventional antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotics (Group A)
Study: 17432638
Drug: Eye-needling combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye-needling combined with medication
Study: 10069757
Drug: Subcutaneous low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous low-molecular-weight heparin (LMWH), tinzaparin sodium, once-daily dose.
Study: 7992418
Drug: Incision, curettage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision, curettage and primary suture under antibiotic cover
Study: 7992418
Drug: Conventional, 'open'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional, 'open' treatment